Liposomal resiquimod for the treatment of Leishmania donovani infection
Open Access
- 16 August 2013
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 69 (1) , 168-175
Abstract
The imidazoquinoline family of drugs are Toll-like receptor 7/8 agonists that have previously been used in the treatment of cutaneous leishmaniasis. Because of the hydrophobic nature of imidazoquinolines, they are traditionally not administered systemically for the treatment of visceral leishmaniasis. We formulated liposomal resiquimod, an imidazoquinoline, for the systemic treatment of visceral leishmaniasis. By using lipid film hydration with extrusion, we encapsulated resiquimod in liposomes. These liposomes were then injected intravenously to treat BALB/c mice infected with Leishmania donovani. Treatment with liposomal resiquimod significantly decreased the parasite load in the liver, spleen and bone marrow. In addition, resiquimod treatment increased interferon-γ and interleukin-10 production in an antigen recall assay. Resiquimod was shown to be non-toxic in histology and in vitro culture experiments. FDA-approved resiquimod, in a liposomal formulation, displays promising results in treating visceral leishmaniasis.Keywords
This publication has 47 references indexed in Scilit:
- Evaluation of Nephroprotective and Immunomodulatory Activities of Antioxidants in Combination with Cisplatin against Murine Visceral LeishmaniasisPLOS Neglected Tropical Diseases, 2012
- Mechanism of Amphotericin B Resistance in Clinical Isolates of Leishmania donovaniAntimicrobial Agents and Chemotherapy, 2012
- Immunotherapy for Tuberculosis: what's the better choice?Frontiers in Bioscience-Landmark, 2012
- Old World Leishmania infantum Cutaneous Leishmaniasis Unresponsive to Liposomal Amphotericin B Treated With Topical ImiquimodThe Pediatric Infectious Disease Journal, 2012
- Targeting the host–pathogen interface for treatment of Staphylococcus aureus infectionSeminars in Immunopathology, 2011
- Visceral leishmaniasis: immunology and prospects for a vaccineClinical Microbiology and Infection, 2011
- Comparative histological and immunohistochemical changes of dry type cutaneous leishmaniasis after administration of meglumine antimoniate, imiquimod or combination therapy.2011
- Influence of Clinical Status and Parasite Load on Erythropoiesis and Leucopoiesis in Dogs Naturally Infected with Leishmania (Leishmania) chagasiPLOS ONE, 2011
- Cellular and Molecular Mechanisms Underlying the Strong Neonatal IL-12 Response of Lamb Mesenteric Lymph Node Cells to R-848PLOS ONE, 2010
- CpG oligodeoxynucleotide augments the antileishmanial activity of miltefosine against experimental visceral leishmaniasisJournal of Antimicrobial Chemotherapy, 2010